Pills and injections serve us well, but for a patient with a chronic illness like diabetes or heart disease, they are less than perfect. Dosages don’t always match the body’s fluctuating needs, and it’s easy to forget to take a pill. But what if doctors could implant a small capsule under your skin that could detect, say, changes in blood sugar levels or some heart disease-related molecule and then release the exact amount of medication needed to keep your illness in check? That’s the idea behind a new generation of “smart” drug-delivery devices being worked on by a number of research labs. One of the challenges in making these devices practical is building valves capable of releasing precise amounts of medications from the device’s reservoir.
To overcome that hurdle, Ohio State University’s Marc Madou, professor of materials science and engineering, is using capsules equipped with tiny muscles. Madou and his group have developed “artificial muscles” that cover microscopic perforations in the 2.5-centimeter-long plastic capsule. The muscles-made of a porous, gel-like polymer-shrink and swell on command, controlling tiny trapdoors that swing shut to cover each perforation. “We got the idea from a kid’s toy, those miniature sponges that expand when you drop them in water,” says Madou. Apply a negative voltage and the muscles contract, opening the trapdoors and releasing the drug; apply a positive voltage and the muscles expand, shutting the doors and cutting off the flow.
While Madou’s artificial muscle attempts to solve just one part of the drug-delivery puzzle, his team’s ultimate goal is to fabricate implantable capsules that come equipped not only with muscles, but also with tiny sensors, a battery and maybe even a microprocessor. The idea is that sensors would detect physiological changes in the body and relay a message to the battery, which would in turn produce the voltage to open or close the trapdoor. “Or instead of having sensors, the time of every dosage could be programmed into a chip, so that the right amount of drug is released at the right time,” he says. Madou has co-founded a company, ChipRx, to commercialize the technology; company executives predict animal trials will begin in three to four years.
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.